论文部分内容阅读
目的:观察柔肝消癥饮对肝硬化大鼠肝组织病理形态学和血清、肝组织IL-1β、IL-6含量的影响。方法:采用复合因素造模法复制肝硬化大鼠模型,以复方鳖甲软肝片为对照,观察柔肝消癥饮对肝硬化大鼠肝组织病理形态学、血清和肝组织IL-1β、IL-6含量的影响。结果:与正常组比较,模型组大鼠出现肝小叶损害,纤维组织增生,假小叶形成,血清IL-1β、IL-6含量和肝组织IL-6含量均明显升高(P<0.01或P<0.05);与模型组比较,各治疗组肝组织病理损害减轻,血清IL-1β和肝组织IL-6含量均有明显下降,差异有显著性意义(P<0.01或P<0.05);与对照组比较,高剂量组血清IL-6含量明显降低(P<0.05)。结论:柔肝消癥饮能显著下调肝硬化大鼠血清IL-1β、IL-6含量和肝组织IL-6含量,具有减轻肝硬化炎症损害,改善肝组织病理形态学作用。
Objective: To observe the effect of Rougan Xiaozheng decoction on liver pathological morphology, serum and liver IL-1β and IL-6 levels in rats with cirrhosis. METHODS: Rat model of liver cirrhosis was duplicated by compound factor modeling. The compound liver Biejia Ruangan Tablets was used as control to observe the pathological morphology of liver tissue of liver cirrhosis rat and the serum and liver IL-1β. The effect of IL-6 content. RESULTS: Compared with the normal group, the rats in the model group presented hepatic lobular lesions, fibrous tissue hyperplasia, pseudo-lobule formation, serum IL-1β, IL-6 levels, and liver tissue IL-6 levels were significantly increased (P<0.01 or P). <0.05);Compared with the model group, the pathological lesions of liver tissue in all treatment groups were reduced, serum IL-1β and liver tissue IL-6 content were significantly decreased, the difference was significant (P<0.01 or P<0.05); Compared with the control group, serum IL-6 levels in the high-dose group were significantly lower (P<0.05). Conclusion: Rougan Xiaozheng decoction can significantly down-regulate the serum levels of IL-1β, IL-6 and IL-6 in liver tissue of rats with cirrhosis, and it can reduce the inflammatory lesions of liver cirrhosis and improve the pathological morphology of liver tissue.